Martin Bonde, PhD

Chief Executive Officer

Martin Bonde is our CEO and has worked in Inthera since June 2020. With 25+ years of international experience from the biotech industry, Martin has held several leadership positions as CEO for e.g. Vaccibody AS (now Nykode Therapeutics AS, Euronext Growth Oslo:VACC), Epitherapeutics Aps (sold to Gilead Sciences, Inc.), NatImmune A/S (sold to Azanta A/S), Combio A/S (sold to Arpida AG), Torsana Biosensor (sold to Celtor Bioscience, Inc.), and Osteometer Biotech (now Nordic Bioscience A/S). Martin serves on the Board of Directors in privately held digital pathology software company Visiopharm A/S, and in BioInnovation Institute (BII), an international life science incubator funded by the Novo-Nordisk Foundation. He also serves as Chairman of the Board of Directors in Asgard Therapeutics, a privately held Swedish cell reprogramming company working in the oncology field. Martin holds a Master of Science and Ph.D in Chemical Engineering from the Technical University of Denmark as well as a Graduate Diploma in Business Administration (HD i Udenrigshandel) from Copenhagen Business School.